Journey Medical (DERM) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $0.97.
- Journey Medical's Debt to Equity fell 4635.22% to $0.97 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.97, marking a year-over-year decrease of 4635.22%. This contributed to the annual value of $1.24 for FY2024, which is 7253.01% up from last year.
- Journey Medical's Debt to Equity amounted to $0.97 in Q3 2025, which was down 4635.22% from $1.3 recorded in Q2 2025.
- Journey Medical's Debt to Equity's 5-year high stood at $1988.4 during Q2 2023, with a 5-year trough of -$1.28 in Q3 2021.
- Its 5-year average for Debt to Equity is $125.17, with a median of $1.15 in 2024.
- As far as peak fluctuations go, Journey Medical's Debt to Equity skyrocketed by 46759673.49% in 2023, and later tumbled by 9991.21% in 2024.
- Journey Medical's Debt to Equity (Quarter) stood at $0.02 in 2021, then surged by 6843.66% to $1.34 in 2022, then plummeted by 46.42% to $0.72 in 2023, then skyrocketed by 72.53% to $1.24 in 2024, then dropped by 21.64% to $0.97 in 2025.
- Its Debt to Equity was $0.97 in Q3 2025, compared to $1.3 in Q2 2025 and $1.16 in Q1 2025.